AACR 2023 Conference Coverage

 

AACR 2023 Conference Coverage
J

A Personalized Cancer Vaccine mRNA-4157 + Pembro vs. Pembro in Resected HR-Melanoma: Efficacy & Safety Results From the Randomized, Open-Label Phase 2 mRNA-4157-P201/KEYNOTE-942 Trial

By AACR 2023 Conference Coverage FEATURING Jeffrey Weber
By AACR 2023 Conference Coverage FEATURING Jeffrey Weber
0 views
May 9, 2023
Comments 0
Login to view comments. Click here to Login

Featured Video

09:36
Johnson & Johnson

Mechanisms of Resistance in Locally Advanced or Metastatic EGFR+ NSC…

Feat. J. Heymach, M. Das

Featured Video

06:27
Johnson & Johnson

Challenges to Navigate in Locally Advanced or Metastatic EGFR+ NSCLC

Feat. M. Socinski, D. Waterhouse
Videos
11:12
AACR 2023 Conference Coverage

Tumor-Agnostic Precision Medicine from the AACR GENIE Database: Clin…

Feat. M. Gouda
12:13
AACR 2023 Conference Coverage

Clinical Activity of MCLA-158 (Petosemtamab), an IgG1 Bispecific Ant…

Feat. E. Cohen
10:22
AACR 2023 Conference Coverage

Understanding the Disease Biology of B-ALL: Insights From Genomic an…

Feat. I. Iacobucci
09:13
AACR 2023 Conference Coverage

Safety & Efficacy From the Phase 1/2 First-in-Human Study of REG…

Feat. A. Suvannasankha
09:05
AACR 2023 Conference Coverage

AACR 2023 on KEYNOTE-966 Phase 3 Study: Pembro in Combination With G…

Feat. K. Kelley
16:00
AACR 2023 Conference Coverage

A Personalized Cancer Vaccine mRNA-4157 + Pembro vs. Pembro in Resec…

Feat. J. Weber
13:53
AACR 2023 Conference Coverage

First-in-Class, First-in-Human Phase 1 Trial of VT3989, an Inhibitor…

Feat. T. Yap